CAR-T treatments emerged as a major success for the pharma industry when first approved in 2017, but this has been muddied by concerns over secondary malignancies.
On International Women’s Day, pharmaphorum looks back to an interview with Miruna Sasu, PhD, CEO of COTA, a real-world data company that is advancing generative AI models for cancer care.
As Vice President of Cancer Biomarker Development at AstraZeneca, Jorge Reis-Filho seeks to develop and validate the next generation of mechanistically informed and clinically deployable bi
Sage Therapeutics has suffered another disappointment after deciding that it will have to drop the Parkinson’s programme for key pipeline drug dalzanemdor after it showed
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.